title: Pyrophosphate inhibition of Proteus mirabilis-induced struvite crystallization in vitro.
abstract: Struvite (MgNH4PO4.6H2O) crystals, the major mineral component of infectious urinary calculi, were produced in vitro by growth of a clinical isolate of Proteus mirabilis in artificial urine. P. mirabilis growth and urease-induced struvite production were monitored by phase contrast light microscopy and measurements of urease activity, pH, ammonia concentrations, turbidity, and culture viability. In the absence of pyrophosphate, struvite crystals appeared within 3-5 h due to the urease-induced elevation of pH and initially assumed a planar or 'X-shaped' crystal habit (morphology) characteristic of rapid growth. When pyrophosphate was present, initial precipitation and crystal appearance were significantly impaired and precipitates were largely amorphous. When crystals did appear (usually after 7 or 8 h) they were misshapen or octahedral in shape indicative of very slow growth. X-ray diffraction and Fourier transform infrared spectroscopy (FTIR) identified all crystals as struvite. Trace contaminates of carbonate-apatite (Ca10(PO4)6CO3) or newberyite (MgHPO4.H2O) were produced only in the absence of pyrophosphate. P. mirabilis viability and culture pH elevation were unaffected by the addition of pyrophosphate, whereas urease activity and ammonia concentrations were marginally reduced. Struvite could also be produced chemically by titration of the artificial urine with NH4OH. If pyrophosphate was present during titration, the same inhibitory effect on crystal growth occurred, so it is unlikely that urease inhibition is important. Lowering of pyrophosphate concentration from 13-0.45 mumol/l did not reduce its inhibitory activity so it is unlikely to act by chelating free Mg2+. We propose that pyrophosphate inhibits struvite growth principally through direct interference with the chemical mechanisms involved in crystal nucleation and growth, because of its effectiveness at very low concentrations.
authors.affiliation: Department of Urology, Queen's University, Kingston, Ontario, Canada.
authors.forename: R J
authors.initials: RJ
authors.lastname: McLean
authors.forename: J
authors.initials: J
authors.lastname: Downey
authors.forename: L
authors.initials: L
authors.lastname: Clapham
authors.forename: J W
authors.initials: JW
authors.lastname: Wilson
authors.forename: J C
authors.initials: JC
authors.lastname: Nickel
mesh_terms: D000641:Ammonia / Q000378:metabolism; D003460:Crystallization; D003461:Crystallography; D011756:Diphosphates / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006490:Hemostatics; D006863:Hydrogen-Ion Concentration; D008274:Magnesium / Q000378:metabolism; D017616:Magnesium Compounds; D010710:Phosphates / Q000378:metabolism; D011513:Proteus mirabilis / Q000378:metabolism*; D013055:Spectrophotometry, Infrared; D000069877:Struvite; D014545:Urinary Calculi / Q000378:metabolism*; D014556:Urine / Q000502:physiology
chemical_list: D011756:Diphosphates; D006490:Hemostatics; D017616:Magnesium Compounds; D010710:Phosphates; D000641:Ammonia; D000069877:Struvite; D008274:Magnesium